Life Sciences Sector Plan One Year On: Realising the UK's Life Sciences Growth Ambition 

One year after the publication of the Life Sciences Sector Plan, the All-Party Parliamentary Group (APPG) for Life Sciences brought together a panel of key leaders from across the sector to celebrate progress so far, identify key areas of focus for the future and discuss how to work together to deliver on the ambitions of the Plan.  

The Government has set ambitious targets to make the UK the leading life sciences economy in Europe by 2030 through increased commercial R&D investment, greater access to scale-up capital, faster patient access to innovation and higher levels of foreign direct investment. The introduction of clear delivery metrics, accountable leadership and ambitious reforms has created positive momentum, with notable progress in regulatory reform, manufacturing investment, clinical trial performance and the development of the Health Data Research Service. These achievements demonstrate that government has successfully established the policy foundations for growth. However, these reforms have yet to deliver the system-wide transformation required to position the UK as the world's leading destination for life sciences investment and innovation. 

While policy has advanced significantly over the past year, the panel discussion highlighted that the greatest challenges now lie not in strategy but in implementation. In particular, slow and inconsistent adoption of innovation across the NHS, insufficient support for commercialisation, and a narrow approach to assessing the value of health investment risk limiting both economic growth and patient benefit. 

NHS Adoption Must Become a Growth Priority 

The strongest theme throughout the discussion was that slow and inconsistent adoption of innovation across the NHS remains the greatest barrier to the UK's life sciences ambitions. The Government has committed to making the UK one of the three fastest countries in Europe for patient access to medicines and medical technologies by 2030. Achieving this ambition will depend not only on regulatory performance, but on addressing the longstanding barriers to adoption within the NHS.  

While the UK continues to produce world-leading science, patients are often slow to benefit from new medicines, diagnostics and technologies, weakening the UK's attractiveness as a place to invest. Participants argued that faster adoption requires stronger national leadership, clearer accountability and procurement systems that reward innovation. The Budget should therefore support measures that accelerate the uptake of proven technologies across the NHS, providing greater certainty for innovators while improving outcomes for patients. 

Recognising Health as an Economic Investment 

A recurring message was that government should take a broader view of the value generated by health innovation. Current approaches often focus on immediate healthcare costs rather than recognising the wider economic benefits of innovation, including higher productivity, increased labour market participation, reduced long-term public spending and greater inward investment. 

As one of the UK's highest-value sectors, life sciences should be recognised as a driver of economic growth as well as improved health. HM Treasury should ensure that future investment decisions better reflect these wider economic impacts. 

Strengthening the UK's Commercial Environment 

The Sector Plan commits to making the UK Europe's leading destination for commercial life sciences R&D investment and foreign direct investment by 2030. The discussion highlighted the need to create a more competitive environment for investment and commercialisation. Although the UK has a strong scientific base and a globally respected regulatory system, many innovative companies continue to face difficulties accessing the capital and support needed to scale domestically. As a result, promising research is too often commercialised overseas. 

The Government has also committed to making the UK Europe's leading destination for life sciences scale-up capital by 2030. While investment into UK biotech has strengthened, the government should strengthen support for commercialisation, scale-up finance and translational research, ensuring that the UK captures the economic benefits of its world-leading science. 

Building on Clinical Trial Success 

The Government has already established a clear vision through the Life Sciences Sector Plan and committed to ambitious, measurable targets for commercial R&D. Participants welcomed the progress made in improving clinical trial performance but agreed that greater ambition is now required. Patient recruitment remains a significant weakness and continues to limit the UK's competitiveness. Better use of NHS data, digital infrastructure and the forthcoming Health Data Research Service offers an opportunity to transform research delivery and attract further global investment. 

Continued investment in research infrastructure and workforce capability will be essential if the UK is to become a global leader in commercial clinical research. 

Conclusion 

The panel discussion highlighted that future success will depend less on new strategies and more on creating the conditions that allow innovation to be adopted more quickly, research to be commercialised more effectively and investment to flourish. 

The life sciences industry is uniquely placed to support the Government's missions on economic growth, productivity and public service reform. Investment in research, innovation and adoption should therefore be recognised not solely as health expenditure, but as a long-term investment in national prosperity. The upcoming Budget should provide a framework that enables the UK to capitalise on its world-leading science, strengthen its international competitiveness and deliver greater value for patients, the NHS and the wider economy.